About 1-800-PetMeds (NASDAQ:PETS)
PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies through its Website. It markets its products through Internet; telephone contact center; and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards under various brands. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryInternet Retail
SectorRetail/Wholesale
SymbolNASDAQ:PETS
CUSIP71638210
Phone561-526-4444
Debt
Debt-to-Equity RatioN/A
Current Ratio4.24%
Quick Ratio3.36%
Price-To-Earnings
Trailing P/E Ratio29.77
Forward P/E Ratio19.68
P/E Growth1.61
Sales & Book Value
Annual Sales$249.18 million
Price / Sales2.88
Cash Flow$1.2351 per share
Price / Cash28.20
Book Value$4.55 per share
Price / Book7.65
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$23.81 million
Net Margins12.84%
Return on Equity34.04%
Return on Assets27.74%
Miscellaneous
Employees187
Outstanding Shares20,600,000
1-800-PetMeds (NASDAQ:PETS) Frequently Asked Questions
What is 1-800-PetMeds' stock symbol?
1-800-PetMeds trades on the NASDAQ under the ticker symbol "PETS."
How often does 1-800-PetMeds pay dividends? What is the dividend yield for 1-800-PetMeds?
1-800-PetMeds declared a quarterly dividend on Monday, January 22nd. Shareholders of record on Monday, February 5th will be paid a dividend of $0.25 per share on Friday, February 16th. This represents a $1.00 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, February 2nd. This is an increase from 1-800-PetMeds's previous quarterly dividend of $0.20. View 1-800-PetMeds' Dividend History.
How were 1-800-PetMeds' earnings last quarter?
1-800-PetMeds (NASDAQ:PETS) posted its quarterly earnings data on Monday, October, 23rd. The company reported $0.43 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.13. The firm had revenue of $66.70 million for the quarter, compared to analysts' expectations of $63.41 million. 1-800-PetMeds had a return on equity of 34.04% and a net margin of 12.84%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. View 1-800-PetMeds' Earnings History.
When is 1-800-PetMeds' next earnings date?
What price target have analysts set for PETS?
5 Wall Street analysts have issued twelve-month target prices for 1-800-PetMeds' stock. Their forecasts range from $19.00 to $58.00. On average, they anticipate 1-800-PetMeds' share price to reach $41.00 in the next twelve months. View Analyst Ratings for 1-800-PetMeds.
Who are some of 1-800-PetMeds' key competitors?
Who are 1-800-PetMeds' key executives?
1-800-PetMeds' management team includes the folowing people:
- Mr. Menderes Akdag, Chief Exec. Officer, Pres & Director (Age 57)
- Mr. Bruce S. Rosenbloom, CFO, Principal Accounting Officer & Treasurer (Age 49)
- Ms. Alison Berges, Corp. Sec. & Gen. Counsel
Has 1-800-PetMeds been receiving favorable news coverage?
News articles about PETS stock have been trending positive recently, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. 1-800-PetMeds earned a news sentiment score of 0.41 on Accern's scale. They also gave press coverage about the company an impact score of 45.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of 1-800-PetMeds?
Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 1-800-PetMeds' stock price today?
One share of PETS stock can currently be purchased for approximately $34.83.
How big of a company is 1-800-PetMeds?
1-800-PetMeds has a market capitalization of $712.59 million and generates $249.18 million in revenue each year. The company earns $23.81 million in net income (profit) each year or $1.17 on an earnings per share basis. 1-800-PetMeds employs 187 workers across the globe.
How can I contact 1-800-PetMeds?
1-800-PetMeds' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at 561-526-4444.
MarketBeat Community Rating for 1-800-PetMeds (PETS)
MarketBeat's community ratings are surveys of what our community members think about 1-800-PetMeds and other stocks. Vote "Outperform" if you believe PETS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETS will underperform the S&P 500 over the long term. You may vote once every thirty days.
1-800-PetMeds (NASDAQ:PETS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for 1-800-PetMeds in the last 12 months. Their average twelve-month price target is $41.00, suggesting that the stock has a possible upside of 17.71%. The high price target for PETS is $58.00 and the low price target for PETS is $19.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.20 | 2.20 | 2.20 | 2.20 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $41.00 | $41.00 | $41.00 | $40.00 |
| Price Target Upside: | 17.71% upside | 12.77% downside | 12.77% downside | 14.55% upside |
1-800-PetMeds (NASDAQ:PETS) Consensus Price Target History
1-800-PetMeds (NASDAQ:PETS) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
1-800-PetMeds (NASDAQ:PETS) Dividend Information
1-800-PetMeds pays an annual dividend of $1.00 per share, with a dividend yield of 2.87%. PETS's most recent quarterly dividend payment was Friday, February 16. 1-800-PetMeds pays out 85.47% of its earnings out as a dividend.
| Most Recent Dividend: | 2/16/2018 |
| Annual Dividend: | $1.00 |
| Dividend Yield: | 2.87% |
| Payout Ratio: | 85.47% (Trailing 12 Months of Earnings)
56.50% (Based on This Year's Estimates)
46.51% (Based on Next Year's Estimates)
|
1-800-PetMeds (NASDAQ:PETS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/22/2018 | quarterly | $0.25 | 2.4% | 2/2/2018 | 2/5/2018 | 2/16/2018 |
| 10/24/2017 | quarterly | $0.20 | 2.08% | 11/3/2017 | 11/6/2017 | 11/17/2017 |
| 7/24/2017 | quarterly | $0.20 | 1.66% | 8/3/2017 | 8/7/2017 | 8/18/2017 |
| 5/8/2017 | quarterly | $0.20 | | 5/17/2017 | 5/19/2017 | 5/26/2017 |
| 1/23/2017 | quarterly | $0.19 | 3.61% | 2/2/2017 | 2/6/2017 | 2/17/2017 |
| 10/24/2016 | quarterly | $0.19 | 3.84% | 11/3/2016 | 11/7/2016 | 11/18/2016 |
| 7/25/2016 | quarterly | $0.19 | 3.71% | 8/4/2016 | 8/8/2016 | 8/19/2016 |
| 5/9/2016 | quarterly | $0.19 | 3.9% | 5/18/2016 | 5/20/2016 | 5/27/2016 |
| 1/25/2016 | quarterly | $0.18 | 4.04% | 2/4/2016 | 2/8/2016 | 2/19/2016 |
| 10/19/2015 | quarterly | $0.18 | 4.28% | 10/29/2015 | 11/2/2015 | 11/13/2015 |
| 7/20/2015 | quarterly | $0.18 | 4.23% | 7/30/2015 | 8/3/2015 | 8/14/2015 |
| 5/4/2015 | quarterly | $0.18 | 4.41% | 5/13/2015 | 5/15/2015 | 5/22/2015 |
| 1/20/2015 | quarterly | $0.17 | 4.2% | 1/30/2015 | 2/3/2015 | 2/13/2015 |
| 10/20/2014 | quarterly | $0.17 | | 10/30/2014 | 11/3/2014 | 11/14/2014 |
| 7/21/2014 | quarterly | $0.17 | 4.79% | 7/31/2014 | 8/4/2014 | 8/15/2014 |
| 5/5/2014 | quarterly | $0.17 | 5.22% | 5/14/2014 | 5/16/2014 | 5/23/2014 |
| 1/30/2014 | quarterly | $0.17 | 5.14% | 2/10/2014 | 2/12/2014 | 2/21/2014 |
| 10/28/2013 | quarterly | $0.17 | 4.56% | 11/6/2013 | 11/8/2013 | 11/22/2013 |
| 7/26/2013 | quarterly | $0.17 | 4.16% | 8/8/2013 | 8/12/2013 | 8/23/2013 |
| 5/3/2013 | quarterly | $0.15 | 4.65% | 5/13/2013 | 5/15/2013 | 5/24/2013 |
| 1/28/2013 | quarterly | $0.15 | 4.64% | 2/6/2013 | 2/8/2013 | 2/22/2013 |
(Data available from 1/1/2013 forward)
1-800-PetMeds (NASDAQ PETS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 90.65%
1-800-PetMeds (NASDAQ PETS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/29/2018 | Ronald J Korn | Director | Sell | 5,000 | $48.38 | $241,900.00 | 68,833 |  |
| 1/22/2018 | Menderes Akdag | CEO | Sell | 10,000 | $57.00 | $570,000.00 | 470,000 | |
| 1/11/2018 | Menderes Akdag | CEO | Sell | 30,000 | $51.00 | $1,530,000.00 | 490,000 | |
| 12/15/2017 | Gian Fulgoni | Director | Sell | 20,000 | $44.38 | $887,600.00 | 55,900 | |
| 10/27/2017 | Ronald J Korn | Director | Sell | 1,000 | $35.57 | $35,570.00 | 73,833 | |
| 8/1/2017 | Robert C Schweitzer | Director | Sell | 2,500 | $49.18 | $122,950.00 | 88,834 | |
| 7/28/2017 | Ronald J Korn | Director | Sell | 5,000 | $48.18 | $240,900.00 | 67,333 | |
| 7/27/2017 | Bruce S Rosenbloom | CFO | Sell | 6,833 | $50.18 | $342,879.94 | 18,534 | |
| 7/27/2017 | Robert C Schweitzer | Director | Sell | 5,000 | $48.60 | $243,000.00 | 83,834 | |
| 5/16/2017 | Frank J Formica | Director | Sell | 5,000 | $35.32 | $176,600.00 | 46,000 | |
| 5/10/2017 | Gian Fulgoni | Director | Sell | 35,000 | $32.22 | $1,127,700.00 | 68,400 | |
| 5/8/2017 | Bruce S Rosenbloom | Insider | Sell | 9,000 | $27.00 | $243,000.00 | 25,267 | |
| 5/1/2017 | Bruce S Rosenbloom | Insider | Sell | 1,500 | $24.00 | $36,000.00 | 34,267 | |
| 12/13/2016 | Menderes Akdag | CEO | Sell | 10,000 | $23.00 | $230,000.00 | 520,000 | |
| 12/9/2016 | Bruce S Rosenbloom | Insider | Sell | 1,500 | $23.00 | $34,500.00 | 35,767 | |
| 12/7/2016 | Menderes Akdag | CEO | Sell | 3,107 | $22.75 | $70,684.25 | 532,674 | |
| 11/25/2016 | Menderes Akdag | CEO | Sell | 6,274 | $22.25 | $139,596.50 | 550,000 | |
| 11/16/2016 | Frank J Formica | Director | Sell | 10,000 | $21.75 | $217,500.00 | 51,000 | |
| 11/14/2016 | Bruce S Rosenbloom | Insider | Sell | 3,000 | $21.75 | $65,250.00 | 38,767 | |
| 11/14/2016 | Menderes Akdag | CEO | Sell | 40,000 | $21.63 | $865,200.00 | 590,000 | |
| 10/10/2016 | Bruce S Rosenbloom | Insider | Sell | 1,500 | $21.00 | $31,500.00 | 41,767 | |
| 10/10/2016 | Menderes Akdag | CEO | Sell | 10,000 | $21.00 | $210,000.00 | 600,000 | |
| 9/22/2016 | Menderes Akdag | CEO | Sell | 10,000 | $20.75 | $207,500.00 | 610,000 | |
| 8/12/2016 | Bruce S Rosenbloom | Insider | Sell | 8,000 | $20.38 | $163,040.00 | 43,267 | |
| 8/11/2016 | Robert C Schweitzer | Director | Sell | 3,000 | $20.59 | $61,770.00 | 90,334 | |
| 8/9/2016 | Robert C Schweitzer | Director | Sell | 4,500 | $20.52 | $92,340.00 | 94,834 | |
| 8/1/2016 | Ronald J Korn | Director | Sell | 4,000 | $20.76 | $83,040.00 | 75,333 | |
| 5/9/2016 | Bruce S Rosenbloom | CFO | Sell | 5,500 | $19.54 | $107,470.00 | 44,767 | |
| 3/30/2016 | Bruce S Rosenbloom | CFO | Sell | 1,500 | $18.00 | $27,000.00 | 46,267 | |
| 3/14/2016 | Bruce S Rosenbloom | CFO | Sell | 3,000 | $17.25 | $51,750.00 | 49,267 | |
| 2/22/2016 | Ronald J Korn | Director | Sell | 5,000 | $16.76 | $83,800.00 | 71,833 | |
| 1/22/2016 | Bruce S Rosenbloom | CFO | Sell | 750 | $18.50 | $13,875.00 | 50,767 | |
| 11/20/2015 | Ronald J Korn | Director | Sell | 1,000 | $17.01 | $17,010.00 | 76,833 | |
| 7/14/2015 | Bruce S Rosenbloom | CFO | Sell | 400 | $18.25 | $7,300.00 | | |
| 7/13/2015 | Bruce S Rosenbloom | CFO | Sell | 100 | $18.25 | $1,825.00 | | |
| 6/19/2015 | Bruce S Rosenbloom | CFO | Sell | 1,000 | $17.88 | $17,880.00 | | |
| 6/19/2015 | Menderes Akdag | CEO | Sell | 8,000 | $17.75 | $142,000.00 | | |
| 6/4/2015 | Menderes Akdag | CEO | Sell | 9,930 | $17.50 | $173,775.00 | | |
| 5/8/2015 | Frank J Formica | Director | Sell | 7,500 | $16.51 | $123,825.00 | | |
| 4/23/2015 | Menderes Akdag | CEO | Sell | 10,000 | $17.25 | $172,500.00 | | |
| 4/20/2015 | Menderes Akdag | CEO | Sell | 10,000 | $17.00 | $170,000.00 | | |
| 4/13/2015 | Menderes Akdag | CEO | Sell | 7,499 | $16.75 | $125,608.25 | | |
| 4/13/2015 | Ronald J Korn | Director | Sell | 2,000 | $16.75 | $33,500.00 | | |
| 4/8/2015 | Menderes Akdag | CEO | Sell | 2,501 | $16.75 | $41,891.75 | | |
| 3/30/2015 | Menderes Akdag | CEO | Sell | 10,000 | $16.50 | $165,000.00 | | |
| 3/25/2015 | Ronald J Korn | Director | Sell | 2,000 | $16.25 | $32,500.00 | | |
| 1/21/2015 | Menderes Akdag | CEO | Sell | 60,000 | $15.63 | $937,800.00 | | |
| 1/20/2015 | Bruce S Rosenbloom | CFO | Sell | 2,167 | $15.40 | $33,371.80 | | |
| 8/15/2014 | Ronald J Korn | Director | Sell | 2,000 | $14.13 | $28,260.00 | | |
| 7/22/2014 | Bruce S Rosenbloom | CFO | Sell | 1,000 | $14.13 | $14,130.00 | | |
| 7/21/2014 | Bruce S Rosenbloom | CFO | Sell | 500 | $14.00 | $7,000.00 | | |
| 6/12/2014 | Bruce S Rosenbloom | CFO | Sell | 1,500 | $13.50 | $20,250.00 | | |
| 9/13/2013 | Menderes Akdag | CEO | Sell | 10,000 | $17.00 | $170,000.00 | 618,000 | |
| 9/11/2013 | Bruce S Rosenbloom | CFO | Sell | 6,666 | $16.21 | $108,055.86 | | |
| 8/14/2013 | Ronald Korn | Director | Sell | 1,000 | $16.25 | $16,250.00 | 72,833 | |
| 8/12/2013 | Ronald Korn | Director | Sell | 1,000 | $16.18 | $16,180.00 | 73,833 | |
| 7/31/2013 | Frank J Formica | Director | Sell | 7,000 | $16.39 | $114,730.00 | | |
| 7/22/2013 | Bruce S Rosenbloom | CFO | Sell | 6,250 | $16.74 | $104,625.00 | | |
| 3/6/2013 | Ronald J Korn | Director | Sell | 2,000 | $13.50 | $27,000.00 | | |
(Data available from 1/1/2013 forward)
1-800-PetMeds (NASDAQ PETS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | PetMed Express (PETS) is Oversold: Can It Recover?
finance.yahoo.com - April 26 at 5:22 PM |
 | Brokerages Anticipate 1-800-PetMeds (PETS) Will Post Quarterly Sales of $67.55 Million
www.americanbankingnews.com - April 26 at 4:34 AM |
| PetMed Express Inc (NASDAQ:PETS) Investors Are Paying Above The Intrinsic Value
finance.yahoo.com - April 25 at 8:11 AM |
| 1-800-PetMeds (PETS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 25 at 12:24 AM |
| Brokerages Expect 1-800-PetMeds (PETS) to Announce $0.44 Earnings Per Share
www.americanbankingnews.com - April 24 at 8:08 AM |
| The Zacks Analyst Blog Highlights: Etsy, eBay, Amazon and PetMed Express
finance.yahoo.com - April 20 at 5:28 PM |
| Contrasting 1-800-PetMeds (PETS) & Express Scripts (ESRX)
www.americanbankingnews.com - April 18 at 5:15 PM |
| 1-800-PetMeds (PETS) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 18 at 9:51 AM |
| Is PetMed Express Inc (NASDAQ:PETS) A Smart Choice For Dividend Investors?
finance.yahoo.com - April 17 at 8:20 AM |
| Financial Review: 1-800-PetMeds (PETS) & Express Scripts (ESRX)
www.americanbankingnews.com - April 14 at 5:11 PM |
| 1-800-PetMeds (PETS) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM |
| Comparing 1-800-PetMeds (PETS) and Express Scripts (ESRX)
www.americanbankingnews.com - April 13 at 7:19 PM |
| 1-800-PetMeds (PETS) Expected to Announce Quarterly Sales of $67.84 Million
www.americanbankingnews.com - April 9 at 3:44 AM |
| Walgreens Boots Alliance (WBA) versus 1-800-PetMeds (PETS) Critical Survey
www.americanbankingnews.com - April 8 at 11:23 AM |
| 1-800-PetMeds (PETS) Downgraded by ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM |
| 1-800-PetMeds (PETS) Expected to Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - April 7 at 8:08 AM |
| 1-800-PetMeds (PETS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 6 at 1:36 AM |
| 1-800-PetMeds (PETS) and Walgreens Boots Alliance (WBA) Critical Analysis
www.americanbankingnews.com - April 4 at 9:21 PM |
| 1-800-PetMeds (PETS) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 10:33 AM |
| 1-800-PetMeds (PETS) vs. Walgreens Boots Alliance (WBA) Financial Survey
www.americanbankingnews.com - April 2 at 7:16 PM |
| Should You Buy PetMed Express Inc (NASDAQ:PETS)?
finance.yahoo.com - March 30 at 5:38 PM |
| Amazon Teams Up With Monoprix, Bolsters Presence in Europe
finance.yahoo.com - March 27 at 5:20 PM |
| Petmed Express (PETS) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - March 25 at 11:21 AM |
| $67.84 Million in Sales Expected for Petmed Express Inc (PETS) This Quarter
www.americanbankingnews.com - March 23 at 9:36 AM |
| Petmed Express Inc (PETS) Expected to Post Earnings of $0.44 Per Share
www.americanbankingnews.com - March 21 at 12:36 PM |
 | Top Ranked Growth Stocks to Buy for March 19th
www.zacks.com - March 20 at 5:23 PM |
 | A New Blackmark for United as Dog Dies in Overhead Bin
www.wsj.com - March 14 at 8:20 AM |
| Does PetMed Express Inc’s (NASDAQ:PETS) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 13 at 7:24 PM |
| Petmed Express Inc (PETS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 12 at 1:55 AM |
| Top 3 Stocks To Buy - Yahoo Finance
finance.yahoo.com - March 8 at 6:55 PM |
| Petmed Express Inc to Post FY2018 Earnings of $1.77 Per Share, Northcoast Research Forecasts (PETS)
www.americanbankingnews.com - March 8 at 9:08 AM |
| Top 3 Stocks To Buy
finance.yahoo.com - March 8 at 8:14 AM |
| Petmed Express Inc (PETS) Stake Lowered by Schroder Investment Management Group
www.americanbankingnews.com - March 6 at 10:52 AM |
| Zacks: Brokerages Expect Petmed Express Inc (PETS) Will Announce Quarterly Sales of $67.64 Million
www.americanbankingnews.com - March 6 at 10:28 AM |
| WINTON GROUP Ltd Has $7.47 Million Position in Petmed Express Inc (PETS)
www.americanbankingnews.com - March 4 at 2:29 PM |
| 95,653 Shares in Petmed Express Inc (PETS) Acquired by Maverick Capital Ltd.
www.americanbankingnews.com - March 4 at 1:40 PM |
| Brokerages Expect Petmed Express Inc (PETS) to Post $0.43 EPS
www.americanbankingnews.com - March 4 at 5:10 AM |
| Landscape Capital Management L.L.C. Buys Shares of 164,420 Petmed Express Inc (PETS)
www.americanbankingnews.com - March 2 at 5:26 PM |
 | PetMed (PET) Focuses on Advertising to Boost New Order Sales - Nasdaq
www.nasdaq.com - February 28 at 8:09 AM |
| Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues
finance.yahoo.com - February 28 at 8:09 AM |
| Smith Asset Management Group LP Acquires 13,189 Shares of Petmed Express Inc (PETS)
www.americanbankingnews.com - February 25 at 2:28 PM |
| Petmed Express (PETS) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - February 25 at 12:34 AM |
| After Wayfair's Earnings Miss, Buy These E-Commerce Stocks Instead
finance.yahoo.com - February 22 at 5:42 PM |
| Why Is PetMed Express (PETS) Down 9.8% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - February 22 at 8:13 AM |
| Petmed Express Inc (PETS) Expected to Post Quarterly Sales of $67.64 Million
www.americanbankingnews.com - February 17 at 10:26 AM |
| Brokerages Expect Petmed Express Inc (PETS) to Announce $0.43 EPS
www.americanbankingnews.com - February 15 at 11:10 AM |
| Petmed Express Inc (PETS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 15 at 1:46 AM |
| DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
finance.yahoo.com - February 14 at 8:58 AM |
| GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates
finance.yahoo.com - February 14 at 8:58 AM |
| Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
finance.yahoo.com - February 8 at 3:38 PM |
1-800-PetMeds (NASDAQ:PETS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
1-800-PetMeds (NASDAQ:PETS) Income Statement, Balance Sheet and Cash Flow Statement
1-800-PetMeds (NASDAQ PETS) Stock Chart for Thursday, April, 26, 2018
Loading chart…
